359P - Activity and safety of a combination of epirubicin, docetaxel and cisplatin as neoadjuvant treatment for locally advanced breast cancer (LABC): a pr...

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Anticancer agents
Breast Cancer
Therapy
Biological therapy
Presenter Nilufer Avci
Authors N. Avci1, O. Kanat1, S. Gokgoz2, S. Tolunay3, U. Topal4, E. Cubukcu1, F. Olmez1
  • 1Medical Oncology, Uludag University Faculty of Medicine, Bursa/TR
  • 2Surgery, Uludag University Faculty of Medicine, Bursa/TR
  • 3Pathology, Uludag University Faculty of Medicine, Bursa/TR
  • 4Radiology, Uludag University Faculty of Medicine, Bursa/TR

Abstract

Aim and background

Efficacy of cisplatin-containing triplet chemotherapy regimens for neoadjuvant therapy of LABC has not been investigated extensively. The aim of this study was to evaluate activity and safety of a combination of epirubicin, docetaxel and cisplatin (ETC) in the neoadjuvant setting.

Patients and methods

Forty-two patients with LABC (T2-T4, N0-N2, M0) were enrolled the study from March 2010 to April 2011. These patients received epirubicin (60 mg/m2 intravenously [I.V.] day 1), docetaxel (60 mg/m2 I.V. day 1) and cisplatin (60 mg/m2 I.V. day 1) every 21 days for at least 4 cycles, plus a final 2 additional cycles. Upon completion of therapy, the primary tumor was resected when not contraindicated. The primary endpoint was the pathological complete response (pCR) rate; seconday endpoints included response rate and toxicity.

Results

Median patients age was 48 years (range, 23-73 years). Median tumor size was 3.2 cm. Thirty-seven patients (88%) received 6 cycles of ETC. The overall clinical response rate was 78.6%. Twenty of 42 patients (47.6%) achieved a complete pathological response (CPR). All tumors became operable after neoadjuvant chemotherapy. The most common side effect was myelotoxicity. WHO grade 4 neutropenia developed in 30 (73%) patients. No recurrence was observed in any patient after a mean follow-up of 17 months (13-21 months).

Conclusion

Although our study group was small and the follow-up period relatively short-term, the considerably high rates of CPR in this preliminary series suggest that ETC regimen may be a promising option in neoadjuvant treatment of LABC. >

Disclosure

All authors have declared no conflicts of interest.